FDAnews
www.fdanews.com/articles/197804-keytruda-approved-for-recurrent-or-metastatic-cutaneous-squamous-cell-carcinoma

Keytruda Approved for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma

June 26, 2020

The FDA has approved Merck’s Keytruda (pembrolizumab) for patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.

The approval is based on the results of a phase 2 clinical trial, in which 31 percent of patients showed a partial response and 4 percent showed a complete response.

Keytruda was approved earlier this month as a monotherapy for patients with unresectable or metastatic tumor mutational burden-high solid tumors.

View today's stories